Impaired capacity for upregulation of MHC class II in tumor‐associated microglia
Jill Schartner(University of Wisconsin–Madison), Behnam Badie(City Of Hope National Medical Center), Nivedita Nadkarni(University of Wisconsin–Madison), Michelle Van Handel(City Of Hope National Medical Center), Aaron R. Hagar(University of Wisconsin–Madison), Leying Zhang(City Of Hope National Medical Center)
Cited by 134
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
|Nature Immunology|2022|529
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
|Frontiers in Immunology|2017|216